Please use this identifier to cite or link to this item:
|Title:||Cancer-specific and all-cause mortality in kidney transplant recipients with and without a prior cancer.|
|Epworth Authors:||Cohney, Solomon (Shlomo)|
|Other Authors:||Viecelli, A.|
|Keywords:||UroRenal, Vascular Clinical Institute, Epworth HealthCare, Victoria, Australia|
Department of Nephrology, Epworth HealthCare, Richmond, Victoria, Australia.
Department of Gastroenterology, Epworth HealthCare, Richmond, Victoria, Australia.
Proportional Hazards Models
Australian and New Zealand Dialysis and Transplant Registry
|Citation:||Transplantation. 2015 Dec;99(12):2586-92.|
|Abstract:||BACKGROUND: For dialysis patients with a cancer history, a period of surveillance is generally recommended before listing for transplantation. However, the outcomes of patients with cancer recurrence and/or a second primary cancer after transplantation are unknown. AIM: To determine the prognosis of kidney transplant recipients who developed cancer after transplantation and whether this varied with cancer types (first cancer, recurrence, second primary cancer). METHODS: Using data from the Australian and New Zealand Dialysis and Transplant Registry, we compared the cancer-specific and all-cause mortality among recipients with different cancer types using adjusted Cox proportional hazard models. RESULTS: Of the 21,415 recipients transplanted between 1965 and 2012, 3% (651 of 21,415) had a previous cancer history. A total of 2840 (13%) recipients developed cancer after the first transplant, of whom 2760 (97.2%) developed a first cancer, 23 (0.8%) experienced cancer recurrence, and 57 (2%) developed a second primary cancer. There were no significant differences in the risks of cancer-specific and all-cause mortality between recipients who developed their first cancer after transplant, those with cancer recurrence (adjusted hazard ratios [aHRs], 0.79; 95% confidence interval [95% CI], 0.38-1.67; P = 0.54 and aHRs, 0.86; 95% CI, 0.45-1.66; P = 0.66, respectively) and recipients who developed a second primary cancer after transplantation (aHRs, 1.01; 95%CI, 0.63-1.62; P = 0.95 and aHRs, 1.16; 95% CI, 0.79-1.69; P = 0.45, respectively). CONCLUSION: Among patients with a previous history of malignancy, recurrent and second primary cancers are infrequent after renal transplantation. A history of previous malignancy does not have an additive effect on the cancer-specific and overall survival of kidney transplant recipients who develop cancer.|
|Affiliated Organisations:||Department of Renal Medicine, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia.|
ANZDATA Registry, Royal Adelaide Hospital, Adelaide, South Australia, Australia.
School of Medicine and Pharmacology, University of Western Australia, Perth, Western Australia, Australia.
Sydney School of Public Health, University of Sydney, New South Wales, Australia.
Centre for Kidney Research, The Children's Hospital at Westmead, New South Wales, Australia.
Department of Nephrology, Western Hospital, University of Melbourne, Victoria, Australia.
Northwestern Academic Centre, University of Melbourne, Victoria, Australia.
Department of Nephrology, Central Northern Adelaide Renal and Transplantation Service, Royal Adelaide Hospital, Adelaide, South Australia, Australia.
Centre for Transplant and Renal Research, Westmead Hospital, New South Wales, Australia.
|Type of Clinical Study or Trial:||Retrospective studies|
|Appears in Collections:||Cancer Services|
Files in This Item:
There are no files associated with this item.
Items in EKB are protected by copyright, with all rights reserved, unless otherwise indicated.